Patent · US Active

Method for the diagnosis of neuromyelitis optica

US10036746B2 · kind B2 · utility

0Cited by

1References

6Claims

0Family size

Assignee

Protagen AG · DE

Inventors

Heike Göhler · Bochum, DE
Petra Rengers · Hachenburg, DE
Angelika Lüking · Bochum, DE
Stefan Mullner · Langenfeld, DE

Key dates

Filing date	Jan 12, 2017
Grant date	Jul 31, 2018
Priority date	—
Expiry date	Jan 12, 2037

Classification

Technology area (CPC G)Physics
CPC primaryG01N2800/56
WIPO fieldMeasurement
WIPO sectorInstruments

Abstract

The present invention relates to a method for the diagnosis and/or risk stratification of neuromyelitis optica (abbreviated NMO), wherein a determination from a body sample of a patient/test subject is performed by means of artificial aquaporin-4 peptides. The invention further relates to a kit and to new artificial aquaporin-4 peptides as such.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.